Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Daniel F. Dilling, Е. Д. Баздырев et al.|The Lancet Respiratory Medicine|2020

Cited by 558